Immune checkpoint blockade therapy in head and neck cancer: a review
DOI:
https://doi.org/10.3329/updcj.v8i2.40384Keywords:
PD1; PDL-1; CTLA4; MHC; T cell, APC.Abstract
Head and neck cancer (HNC) is a common malignant tumor, carrying a poor prognosis, and despite advances in oncology, this rate has not improved significantly for decades. It has recently been evaluated that the immunologic checkpoint inhibitors become a novel promising strategic immunotherapy in the treatment of metastatic cancer. Therefore, our current review article will discuss the biological role and impact of the immune checkpoint inhibitor in HNC.
Update Dent. Coll. j: 2018; 8 (2): 30-33
Downloads
128
21
Downloads
Published
How to Cite
Issue
Section
License
licensing, and copyright:
Articles in Update Dental College Journal are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0. This license permits
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the following license terms.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.